Form 4 for PCVX Vaxcyte, Inc.
Accepted 2022-02-08 00:00:00 ET · period of report 2021-12-20 · accession 0001209191-22-007789 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-08 | 2021-12-20 | PCVX | Fairman Jeff | VP, Research | M - OptEx | $1.79 | +4,469 | 10.6K | +73% | +$8,000 |
| D | 2022-02-08 | 2021-12-20 | PCVX | Fairman Jeff | VP, Research | M - OptEx | $0.00 | -4,469 | 53.6K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-20 | M | A | 4,469 | $1.79 | 10,629 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2021-12-20 | M | D | 4,469 | $0.00 | 53,626 | D | $1.79 · — to 2027-05-17 | 4,469 Common Stock | (F1) The shares subject to the option are fully vested and exercisable. |